These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19482634)

  • 1. Prospects for introducing deferiprone as potent pharmaceutical antioxidant.
    Kontoghiorghes GJ
    Front Biosci (Elite Ed); 2009 Jun; 1(1):161-78. PubMed ID: 19482634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antioxidant targeting by deferiprone in diseases related to oxidative damage.
    Kontoghiorghe CN; Kolnagou A; Kontoghiorghes GJ
    Front Biosci (Landmark Ed); 2014 Jun; 19(6):862-85. PubMed ID: 24896322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
    Kontoghiorghes GJ; Efstathiou A; Kleanthous M; Michaelides Y; Kolnagou A
    Hemoglobin; 2009; 33(5):386-97. PubMed ID: 19814684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
    Kontoghiorghes GJ; Pattichis K; Neocleous K; Kolnagou A
    Curr Med Chem; 2004 Aug; 11(16):2161-83. PubMed ID: 15279556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for the introduction of targeted antioxidant drugs for the prevention and treatment of diseases related to free radical pathology.
    Kontoghiorghes GJ; Kontoghiorghe CN
    Expert Opin Investig Drugs; 2019 Jul; 28(7):593-603. PubMed ID: 31185180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron complexes of deferiprone and dietary plant catechols as cytoprotective superoxide radical scavengers(1).
    Moridani MY; O'Brien PJ
    Biochem Pharmacol; 2001 Dec; 62(12):1579-85. PubMed ID: 11755110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
    Morel I; Cillard J; Lescoat G; Sergent O; Pasdeloup N; Ocaktan AZ; Abdallah MA; Brissot P; Cillard P
    Free Radic Biol Med; 1992 Nov; 13(5):499-508. PubMed ID: 1334028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators.
    Kontoghiorghes GJ
    Arch Toxicol Suppl; 1996; 18():202-14. PubMed ID: 8678796
    [No Abstract]   [Full Text] [Related]  

  • 9. Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology.
    Kontoghiorghe CN; Kolnagou A; Kontoghiorghes GJ
    Molecules; 2015 Nov; 20(11):20841-72. PubMed ID: 26610453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).
    Agarwal MB
    Indian J Pediatr; 1993; 60(4):509-16. PubMed ID: 8262587
    [No Abstract]   [Full Text] [Related]  

  • 11. Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
    Kolnagou A; Kontoghiorghes GJ
    Front Biosci (Landmark Ed); 2018 Jan; 23(6):1082-1098. PubMed ID: 28930590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competition studies of L1-deferiprone with copper and iron. Possible implications on efficacy, toxicity and new therapeutic applications.
    Pashalidis I; Kontoghiorghes GJ
    Transfus Sci; 2000 Dec; 23(3):259-61. PubMed ID: 11099910
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
    Kontoghiorghes GJ
    Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free radical formation and oxyhemoglobin oxidation in beta-thalassemic red blood cells in the presence of prooxidants: effects of the free radical scavenger rutin and oral chelator L1.
    Afanas'ev IB; Afanas'ev II; Deeva IB; Korkina LG
    Transfus Sci; 2000 Dec; 23(3):237-8. PubMed ID: 11099899
    [No Abstract]   [Full Text] [Related]  

  • 15. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Kontoghiorghes GJ; Kolnagou A
    Lancet; 2003 Jan; 361(9352):184. PubMed ID: 12531621
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
    Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
    Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.
    Barnabé N; Zastre JA; Venkataram S; Hasinoff BB
    Free Radic Biol Med; 2002 Jul; 33(2):266-75. PubMed ID: 12106822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.
    Kontoghiorghes GJ
    Indian J Pediatr; 1993; 60(4):485-507. PubMed ID: 8262586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Fe(2+)- and Fe(3+)- induced hydroxyl radical production by the iron-chelating drug deferiprone.
    Timoshnikov VA; Kobzeva TV; Polyakov NE; Kontoghiorghes GJ
    Free Radic Biol Med; 2015 Jan; 78():118-22. PubMed ID: 25451643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.